Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-16T22:44:47.728Z Has data issue: false hasContentIssue false
  • English
  • Français

First-Episode Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Delbert Robinson
Get access Rights & Permissions [Opens in a new window]

Extract

Clinicians treating patients with first-episode (FE) schizophrenia can draw upon the vast literature on the treatment of patients with multiple-episode schizophrenia. Studies with multi-episode patients, however, may not fully generalize to the treatment of FE patients. Studies with multi-episode patients typically recruit from hospitals or other acute care units, settings where patients usually have been either non-responsive or non-adherent to previous treatment, or mixtures of both. Studies of multi-episode patients therefore tend to include patients who are not fully responsive to treatment. Without the filter of prior treatment history, FE compared with multi-episode patients may show a broader range of treatment patterns, ranging from extremely good to very poor. Further, studies of FE patients may be very instructive about side effects, as the confounding effect of prior medication use is particularly important with side effects. Finally, data suggest that much of the deterioration (eg, more severe negative symptoms) associated with schizophrenia may occur during the 5 years following illness onset. Providing patients with better treatment at illness onset offers the hope of improving their long-term outcome.

FE studies do have limitations. Relatively few new cases of schizophrenia occur each year. The typically chronic course of schizophrenia results in a large number of patients with multi-episode schizophrenia for every FE patient at any one time. Recruitment for studies of FE schizophrenia compared with those of multi-episode schizophrenia is often more difficult given the smaller number of available patients. We systematically know less about the treatment of FE patients than we do about the treatment of multi-episode patients.

Type
Research Article
Information
CNS Spectrums , Volume 15 , supplement S6: Practical Dosing Strategies in the Treatment of Schizophrenia , April 2010 , pp. 4 - 7
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Emsley, RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull. 1999;25(4):721–729.CrossRefGoogle ScholarPubMed
2.Lieberman, JA, Phillips, M, Gu, H, et al.Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995–1003.CrossRefGoogle ScholarPubMed
3.Lieberman, JA, Tollefson, G, Tohen, M, et al.Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160(8):1396–1404.CrossRefGoogle ScholarPubMed
4.Schooler, N, Rabinowitz, J, Davidson, M, et al.Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947–953.CrossRefGoogle ScholarPubMed
5.Robinson, DG, Woerner, MG, Napolitano, B, et al.Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006;163(12):2096–2102.CrossRefGoogle ScholarPubMed
6.McEvoy, JP, Lieberman, JA, Stroup, TS, et al.Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–610.CrossRefGoogle Scholar
7.Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796.CrossRefGoogle ScholarPubMed
8.McEvoy, JP, Lieberman, JA, Perkins, DO, et al.Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050–1060.CrossRefGoogle ScholarPubMed
9.Kahn, RS, Fleischhacker, WW, Boter, H, et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–1097.CrossRefGoogle ScholarPubMed
10.Harvey, PD, Rabinowitz, J, Eerdekens, M, Davidson, M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162(10):1888–1895.CrossRefGoogle Scholar
11.Keefe, RS, Seidman, LJ, Christensen, BK, et al.Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;161(6):985–995.CrossRefGoogle ScholarPubMed
12.Keefe, RS, Sweeney, JA, Gu, H, et al.Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1061–1071.CrossRefGoogle ScholarPubMed
13.Davidson, M, Galderisi, S, Weiser, M, et al.Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166(6):675–682.CrossRefGoogle ScholarPubMed
14.Goldberg, TE, Goldman, RS, Burdick, KE, et al.Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64(10):1115–1122.CrossRefGoogle ScholarPubMed
15.Robinson, D, Woerner, MG, Alvir, JM, et al.Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–247.CrossRefGoogle ScholarPubMed
16.Kane, JM, Rifkin, A, Quitkin, F, Nayak, D, Ramos-Lorenzi, J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982;39(1):70–73.CrossRefGoogle ScholarPubMed
17.Crow, TJ, MacMillan, JF, Johnson, AL, Johnstone, EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry. 1986;148:120–127.CrossRefGoogle ScholarPubMed
18.McCreadie, RG, Wiles, D, Grant, S, et al.The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand. 1989;80(6):597–602.Google ScholarPubMed
19.Hogarty, GE, Ulrich, RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res. 1998;32(3–4):243–250.CrossRefGoogle ScholarPubMed
20.Green, AI, Lieberman, JA, Hamer, RM, et al.Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006;86(1–3):234–243.CrossRefGoogle ScholarPubMed
21.Novak-Grubic, V, Tavcar, R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur Psychiatry. 2002;17(3):148–154.CrossRefGoogle ScholarPubMed
22.Coldham, EL, Addington, J, Addington, D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286–290.CrossRefGoogle ScholarPubMed
23.Robinson, DG, Woerner, MG, Alvir, JM, et al.Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2–3):209–219.CrossRefGoogle ScholarPubMed
24.Mutsatsa, SH, Joyce, EM, Hutton, SB, et al.Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 2003;108(6):439–446.CrossRefGoogle ScholarPubMed
25.Kamali, M, Kelly, BD, Clarke, M, et al.A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry. 2006;21(1):29–33.CrossRefGoogle ScholarPubMed
26.Perkins, DO, Johnson, JL, Hamer, RM, et al.Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006;83(1):53–63.CrossRefGoogle ScholarPubMed
27.Verdoux, H, Lengronne, J, Liraud, F, et al.Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102(3):203–210.CrossRefGoogle ScholarPubMed
28.Mojtabai, R, Lavelle, J, Gibson, PJ, et al.Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv. 2002;53(3):337–339.CrossRefGoogle ScholarPubMed
29.Liberman RP, KA, Ventura, J, Gutkind, D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 2002;14(4):256–272.CrossRefGoogle Scholar
30.Robinson, DG, Woerner, MG, McMeniman, M, Mendelowitz, A, Bilder, RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161(3):473–479.CrossRefGoogle ScholarPubMed
31.Craig, TK, Garety, P, Power, P, et al.The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004;329(7474):1067.CrossRefGoogle ScholarPubMed
32.Jeppesen, P, Petersen, L, Thorup, A, et al.Integrated treatment of first-episode psychosis: effect of treatment on family burden: OPUS trial. Br J Psychiatry Suppl. 2005;48:s85–90.CrossRefGoogle ScholarPubMed